Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 14/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30505247 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29413559 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| Hydrochloric Acid SCHEMBL30080174 | 0.99 | MAP2K1 (0.97) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL30022894 | 0.94 | MAP2K1 (0.88) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL28884401 | 0.94 | MAP2K1 (0.88) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29413395 | 0.89 | MAP2K1 (0.80) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL1488448 | 0.89 | MAP2K1 (0.80) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29781341 | 0.88 | MAP2K1 (0.78) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL24195834 | 0.88 | MAP2K1 (0.78) | MAP2K1MAP2K2PIM1CAMK2BIDO1 | |
| SCHEMBL4851710 | 0.88 | MAP2K1 (0.78) | MAP2K1MAP2K2PIM1CAMK2BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230100458-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-30 | — | — | US | claimed |
| US-10407403-B2 | Preparation method of cobimetinib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2019-09-10 | — | — | US | claimed |
| US-20160221975-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-04 | — | — | US | claimed |
| EP-3043790-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | The Administrators of the Tulane Educational Fund (US) | 2016-07-20 | — | — | EP | claimed |
| WO-2015038743-A9 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2015-05-14 | — | — | WO | claimed |
| WO-2015038743-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2015-03-19 | — | — | WO | claimed |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| WO-2006134469-A1 | METHODS OF PREPARING MEK INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2006-12-21 | — | — | WO | claimed |
| US-7060856-B2 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY (US) | 2006-06-13 | — | — | US | claimed |
| US-20260125376-A1 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | GERO THOMAS (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4622947-A1 | ENAMINE N-OXIDE TOOLS FOR TARGET IDENTIFICATION APPLICATIONS | Dana-Farber Cancer Institute, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4598521-A2 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | Dana-Farber Cancer Institute, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2025054260-A1 | INHIBITORS OF MEK KINASE | KINNATE BIOPHARMA INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2003062191-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1313694-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002018319-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | MAP2K1 573/4885MAP2K2 582/4885PIM1 1/4885 |
| US-10407403-B2 | Preparation method of cobimetinib | TET2, ABL1, CBLC | MAP2K1 3629/4885MAP2K2 3468/4885PIM1 893/4885 |
| US-20260125376-A1 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | ARAF, BRAF, RAF1 | MAP2K1 11/4885MAP2K2 14/4885PIM1 591/4885 |
| US-20160221975-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | API5, MAPKAPK5, MAP3K5 | MAP2K1 346/4885MAP2K2 152/4885PIM1 2026/4885 |
| US-20230100458-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | API5, MAPKAPK5, MAP3K5 | MAP2K1 315/4885MAP2K2 144/4885PIM1 1919/4885 |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | MAP2K1 53/4885MAP2K2 51/4885PIM1 174/4885 |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | NRAS, BRAF, KRAS | MAP2K1 72/4885MAP2K2 65/4885PIM1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.